Embecta was not acquired by Becton, Dickinson and Company (BD); rather, embecta was officially spun off from Becton, Dickinson and Company as an independent, publicly traded standalone corporate entity. Following the completion of this tax-free separation, embecta assumed operations of BD's former diabetes care business segment, inheriting its century-long legacy in manufacturing insulin syringes, pen needles, and related diabetes management medical consumables.